P1154: EFFICACY OF SUBCUTANEOUS EPCORITAMAB VS AXI-CEL IN R/R DLBCL CAR T-NAIVE AND CAR T-ELIGIBLE PATIENTS: AN INDIRECT COMPARISON

P1154: EFFICACY OF SUBCUTANEOUS EPCORITAMAB VS AXI-CEL IN R/R DLBCL CAR T-NAIVE AND CAR T-ELIGIBLE PATIENTS: AN INDIRECT COMPARISON

Bibliographic Details
Main Authors:	Catherine Thieblemont, Christopher Fox, Anthony Wang, Kavita Sail, Abualbishr Alshreef, Michael Moran, Alex Mutebi, Julie Blaedel, Viktor Chirikov, Gilles Salles
Format:	Article
Language:	English
Published:	Wiley 2023-08-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000971512.00634.8e

Similar Items

Outcomes of allogeneic hematopoietic stem cell transplantation in R/R DLBCL patients with failure of CAR-T therapy
by: Mengya Cong, et al.
Published: (2024-01-01)

P1215: PRELIMINARY PHASE 1/2 RESULTS OF SUBCUTANEOUS EPCORITAMAB + R-DHAX/C IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT
by: R. Cordoba, et al.
Published: (2022-06-01)

New indications and platforms for CAR‐T therapy in lymphomas beyond DLBCL
by: Madiha Iqbal, et al.
Published: (2022-01-01)

Custom CARs: Leveraging the Adaptability of Allogeneic CAR Therapies to Address Current Challenges in Relapsed/Refractory DLBCL
by: Nikeshan Jeyakumar, et al.
Published: (2022-05-01)

Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy
by: Vera Rentsch, et al.
Published: (2022-05-01)

P1214: SUBCUTANEOUS EPCORITAMAB + R-CHOP FOR FIRST-LINE TREATMENT OF PATIENTS WITH HIGH-RISK DIFFUSE LARGE B-CELL LYMPHOMA: PHASE 1/2 UPDATE
by: M. R. Clausen, et al.
Published: (2022-06-01)

Transformed Lymphoma Is Associated with a Favorable Response to CAR-T-Cell Treatment in DLBCL Patients
by: Anna Nydegger, et al.
Published: (2021-12-01)

CAR-T Cell Therapy Shows Similar Efficacy and Toxicity in Patients With DLBCL Regardless of CNS Involvement
by: Evgenii Shumilov, et al.
Published: (2023-12-01)

CD19-Directed CAR T Cells Treatment in a Patient with Refractory DLBCL and CNS Involvement
by: Antonia Maria S. Müller, et al.
Published: (2019-09-01)

CD19-Directed CAR T Cells Treatment in a Patient with Refractory DLBCL and CNS Involvement
by: Antonia Maria S. Müller, et al.
Published: (2019-09-01)

Complex consequences of Cantu syndrome SUR2 variant R1154Q in genetically modified mice
by: Haixia Zhang, et al.
Published: (2021-03-01)

Accurate In-Vivo Quantification of CD19 CAR-T Cells after Treatment with Axicabtagene Ciloleucel (Axi-Cel) and Tisagenlecleucel (Tisa-Cel) Using Digital PCR
by: Anita Badbaran, et al.
Published: (2020-07-01)

Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment
by: Hilma J. van der Horst, et al.
Published: (2021-02-01)

Durable remission related to CAR-T persistence in R/R B-ALL and long-term persistence potential of prime CAR-T
by: Li Shiqi, et al.
Published: (2023-06-01)

P1135: SUBCUTANEOUS EPCORITAMAB IN COMBINATION WITH RITXUIMAB + LENALIDOMIDE IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: PHASE 1/2 TRIAL UPDATE
by: D. Belada, et al.
Published: (2022-06-01)

Clinical and Product Features Associated with Outcome of DLBCL Patients to CD19-Targeted CAR T-Cell Therapy
by: Sylvain Lamure, et al.
Published: (2021-08-01)

Timely Leukapheresis May Interfere with the “Fitness” of Lymphocytes Collected for CAR-T Treatment in High Risk DLBCL Patients
by: Mirko Farina, et al.
Published: (2022-10-01)

Reflections on the work of C.A.R. Hoare
by: Jones, A, et al.
Published: (2010)

The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL
by: Marion Subklewe, et al.
Published: (2022-05-01)

DLBCL 1L—What to Expect beyond R-CHOP?
by: Maike Stegemann, et al.
Published: (2022-03-01)

Efficacy of CAR-T immunotherapy in MET overexpressing tumors not eligible for anti-MET targeted therapy
by: Cristina Chiriaco, et al.
Published: (2022-10-01)

Croatian Philosophers I: Hermann of Dalmatia (1110–1154)
by: Stipe Kutlesa
Published: (2004-06-01)

Biological Research Factor de Impacto 1,154
by: MANUEL KRAUSKOPF
Published: (2002-01-01)

Comparative analysis of CAR T-cell therapy access for DLBCL patients: associated challenges and solutions in the four largest EU countries
by: Miguel Á. Canales Albendea, et al.
Published: (2023-05-01)

Hypoxia-regulated secretion of IL-12 enhances antitumor activity and safety of CD19 CAR-T cells in the treatment of DLBCL
by: Wenping Zhou, et al.
Published: (2023-09-01)

S222: EPCORITAMAB WITH RITUXIMAB + LENALIDOMIDE (R2) PROVIDES DURABLE RESPONSES IN PATIENTS WITH HIGH-RISK FOLLICULAR LYMPHOMA, REGARDLESS OF POD24 STATUS
by: Anna Sureda, et al.
Published: (2023-08-01)

Serpentine Supravenous Hyperpigmentation in an HIV Patient Receiving R-CHOP for DLBCL
by: Guido Lancman, et al.
Published: (2018-01-01)

P1149: COMPARISON OF THE EFFICACY OF EPCORITAMAB VERSUS CHIMERIC ANTIGEN RECEPTOR THERAPIES, POLATUZUMAB-BASED REGIMENS, AND TAFASITAMAB-BASED REGIMENS
by: Allison Rosenthal, et al.
Published: (2023-08-01)

Cars, cars and more cars [kasetvideo]
Published: ([197)

CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies
by: Yun Liang, et al.
Published: (2021-02-01)

Protein Engineering of Endoglucanase CelR of Clostridium thermocellum for Enhanced Expression
by: Hafiz Muzzammel Rehman, et al.
Published: (2019-02-01)

Circulating tumor DNA determining hyperprogressive disease after CAR-T therapy alarms in DLBCL: a case report and literature review
by: Jiajie He, et al.
Published: (2023-11-01)

PB2333: CAR-T CELL THERAPY IS A EXCELLENT STRATEGY FOR R/R B-NHL
by: Liu Rui, et al.
Published: (2023-08-01)

P1118: LONGER FOLLOW-UP FROM THE PIVOTAL EPCORE NHL-1 TRIAL REAFFIRMS SUBCUTANEOUS EPCORITAMAB INDUCES DEEP, DURABLE COMPLETE REMISSIONS IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA
by: Wojciech Jurczak, et al.
Published: (2023-08-01)

P1169: COMPARISON OF REAL-WORLD CLINICAL OUTCOMES IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA TREATED WITH EPCORITAMAB VS CHEMOIMMUNOTHERAPY
by: Andrew Ip, et al.
Published: (2023-08-01)

A Classical Mind: essays in Honour of C.A.R. Hoare
Published: (1994)

Developing A 2-axis control system for R/C car /
by: 265710 Andelinus Luxman
Published: (1999)

AhR, PXR and CAR: From Xenobiotic Receptors to Metabolic Sensors
by: Leonida Rakateli, et al.
Published: (2023-11-01)

Regulation of cel genes of C. cellulolyticum: identification of GlyR2, a transcriptional regulator regulating cel5D gene expression.
by: Imen Fendri, et al.
Published: (2013-01-01)

106 Treatment with CC-99282 enhances antitumor function of the anti-CD19 CAR T cell therapy lisocabtagene maraleucel (liso-cel)
by: Susan Kim, et al.
Published: (2021-11-01)